NO20081233L - Albumin fusion proteins - Google Patents

Albumin fusion proteins

Info

Publication number
NO20081233L
NO20081233L NO20081233A NO20081233A NO20081233L NO 20081233 L NO20081233 L NO 20081233L NO 20081233 A NO20081233 A NO 20081233A NO 20081233 A NO20081233 A NO 20081233A NO 20081233 L NO20081233 L NO 20081233L
Authority
NO
Norway
Prior art keywords
albumin infusion
proteins
nucleic acids
vectors
fusion proteins
Prior art date
Application number
NO20081233A
Other languages
Norwegian (no)
Inventor
Adam Bell
Yanggu Shi
David Lafleur
Craig Rosen
Paul Moore
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of NO20081233L publication Critical patent/NO20081233L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse omfatter albuminfusjonsproteinet. Nukleinsyremolekylene kodende for albuminfusjonsproteinene av oppfinnelsen er også omsluttet av oppfinnelsen, det er er også vektorer inneholdende disse nukleinsyrene, vertsceller transformert med disse nukleinsyrevektorene og fremgangsmåter for å lage albuminfusjonsproteiner ifølge oppfinnelsen, og å benytte disse nukleinsyrene, vektorene og/eller vertscellene. I tillegg omslutter den foreliggende oppfinnelsen farmasøytiske sammensetninger omfattende albuminfusjonsproteiner og deres fremgangsmåter og behandling, forebygging eller forbedring av sykdommer, lidelser eller tilstander ved å benytte albuminfusjonsproteiner av oppfinnelsen.The present invention comprises the albumin infusion protein. The nucleic acid molecules encoding the albumin infusion proteins of the invention are also encompassed by the invention, there are also vectors containing these nucleic acids, host cells transformed with these nucleic acid vectors and methods of making albumin infusion proteins of the invention, and using these nucleic acids or vectors or nucleic acids. In addition, the present invention encompasses pharmaceutical compositions comprising albumin infusion proteins and their methods and treatment, prevention or amelioration of diseases, disorders or conditions utilizing albumin infusion proteins of the invention.

NO20081233A 2005-08-12 2008-03-10 Albumin fusion proteins NO20081233L (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15
PCT/US2006/029391 WO2007021494A2 (en) 2005-08-12 2006-07-31 Albumin fusion proteins

Publications (1)

Publication Number Publication Date
NO20081233L true NO20081233L (en) 2008-05-09

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081233A NO20081233L (en) 2005-08-12 2008-03-10 Albumin fusion proteins

Country Status (13)

Country Link
EP (1) EP1924596A4 (en)
JP (1) JP2009504157A (en)
KR (1) KR20080071119A (en)
AU (1) AU2006280312A1 (en)
BR (1) BRPI0614761A2 (en)
CA (1) CA2618476A1 (en)
EC (1) ECSP088262A (en)
IL (1) IL189246A0 (en)
MA (1) MA29836B1 (en)
MX (1) MX2008001865A (en)
NO (1) NO20081233L (en)
TN (1) TNSN08064A1 (en)
WO (1) WO2007021494A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2545090T3 (en) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Albumin and GCSF fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
SI1729795T1 (en) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albumin fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2046367A4 (en) 2006-06-07 2009-11-11 Human Genome Sciences Inc Albumin fusion proteins
BRPI0716744A2 (en) * 2006-09-14 2016-10-04 Human Genome Sciences Inc albumin fusion proteins
CA2963138C (en) 2007-01-30 2019-05-14 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
EP2305309A2 (en) 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
KR20110132326A (en) 2009-01-16 2011-12-07 테바 파마슈티컬 인더스트리즈 리미티드 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
SG2014012918A (en) 2009-02-11 2014-04-28 Novozymes Biopharma Dk As Albumin variants and conjugates
KR20100100254A (en) * 2009-03-05 2010-09-15 (주)바이오큐어팜 Composition for preventing or treating cancer comprising human serum albumin-timp-2 fusion protein and anti-cancer agent
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
CN105567699A (en) * 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 Albumin variants
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
JP6200806B2 (en) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド Bispecific fusion protein
WO2012118042A1 (en) * 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター Medicinal agent for inhibiting metastasis of malignant tumor
CN104011072B (en) 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 albumin variants
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
PT2717898T (en) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Pro-coagulant compounds and methods of use thereof
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
CN103826627B (en) 2011-10-21 2016-02-24 艾伯维公司 Comprise the purposes of compositions in the medicine of preparation treatment HCV of at least two kinds of direct antiviral agent and ribavirin
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
BR112014017165B1 (en) 2012-01-12 2023-05-02 Bioverativ Therapeutics Inc CHIMERIC PROTEIN COMPRISING A FACTOR VIII PROTEIN, PHARMACEUTICAL COMPOSITION, AND USES THEREOF
ES2771208T3 (en) 2012-02-15 2020-07-06 Bioverativ Therapeutics Inc Factor VIII compositions and methods of preparation and use thereof
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
EP3693000B1 (en) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Procoagulant compounds
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
CN103525695B (en) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 Portable kidney function detecting system
CN104661674A (en) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 Factor VIII complex with XTEN and von willebrand factor protein, and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US20140128326A1 (en) 2012-11-08 2014-05-08 Novozymes Biopharma Dk A/S Albumin variants
DK2956477T4 (en) 2013-02-15 2024-04-15 Bioverativ Therapeutics Inc OPTIMIZED FACTOR VIII GENE
KR20150118123A (en) 2013-02-16 2015-10-21 노보자임스 바이오파마 디케이 에이/에스 Pharmacokinetic animal model
TWI745671B (en) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 Factor ix polypeptide formulations
SG10201913738YA (en) 2013-06-28 2020-03-30 Bioverativ Therapeutics Inc Thrombin cleavable linker with xten and its uses thereof
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
DK3091997T5 (en) 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc CHIMERIC FACTOR VIII PROTEINS AND USES THEREOF
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
CA2964317C (en) 2014-10-14 2021-10-05 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
CN105254766B (en) * 2015-10-26 2018-10-16 中国航天员科研训练中心 Application of the Mecano growth factor MGF E domain peptides in regulation and control memory related gene and miRNA expression
US11753461B2 (en) 2016-02-01 2023-09-12 Bioverativ Therapeutics Inc. Optimized factor VIII genes
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS
EP3535585A1 (en) 2016-11-04 2019-09-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
JP2019536794A (en) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド Methods for inducing immune tolerance to coagulation factors
EP3548066A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
EP3576762A1 (en) 2017-01-31 2019-12-11 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
MA50141A (en) * 2017-04-20 2020-07-29 Novo Nordisk As ALBUMIN FUSION PROTEIN PURIFICATION PROCESSES
BR112020002394A2 (en) 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. nucleic acid molecules and uses thereof
TW201946929A (en) 2018-02-01 2019-12-16 美商生物化學醫療公司 Use of lentiviral vectors expressing factor VIII
NZ769677A (en) 2018-05-18 2024-07-05 Bioverativ Therapeutics Inc Methods of treating hemophilia a
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
MX2021006648A (en) 2018-12-06 2021-07-07 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor ix.
TW202126284A (en) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 Lentiviral vector formulations
WO2022030580A1 (en) * 2020-08-06 2022-02-10 国立大学法人宮崎大学 Novel long-acting adrenomedullin derivative, method for producing same and pharmaceutical use thereof
JP2024056667A (en) * 2022-10-11 2024-04-23 Ｊｃｒファーマ株式会社 Fusion protein of serum albumin and physiologically active protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003296A2 (en) * 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
ES2545090T3 (en) * 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Albumin and GCSF fusion proteins
SI1729795T1 (en) * 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
WO2007021494A2 (en) 2007-02-22
EP1924596A4 (en) 2009-07-29
KR20080071119A (en) 2008-08-01
EP1924596A2 (en) 2008-05-28
CA2618476A1 (en) 2007-02-22
WO2007021494A3 (en) 2007-07-26
ECSP088262A (en) 2008-05-30
AU2006280312A1 (en) 2007-02-22
JP2009504157A (en) 2009-02-05
MA29836B1 (en) 2008-10-03
BRPI0614761A2 (en) 2009-05-19
TNSN08064A1 (en) 2009-07-14
IL189246A0 (en) 2008-08-07
MX2008001865A (en) 2008-04-15

Similar Documents

Publication Publication Date Title
NO20081233L (en) Albumin fusion proteins
NO20064059L (en) Albumin fusion proteins
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
WO2003059934A3 (en) Albumin fusion proteins
WO2001079443A3 (en) Albumin fusion proteins
WO2007092772A3 (en) Protein formulations
BRPI0511118A (en) untranscribed haemophilus influenzae polypeptides
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
ATE483027T1 (en) RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROKARYONTIC CELLS
BR112014018210A2 (en) Artificial nucleic acid molecules for enhanced protein or peptide expression
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
DK1888641T3 (en) Serum albumin binding proteins
DK2173890T3 (en) Biologically active proteins with increased stability in vivo and / or in vitro
NO20052276L (en) Circulated DNA molecule with a conditional replication origin, method for their preparation and their use in gene therapy
WO2006042158A3 (en) Methods and compositions for improving recombinant protein production
WO2013003641A3 (en) Serpin fusion polypeptides and methods of use thereof
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
WO2022256500A3 (en) Dll3 targeting trispecific proteins and methods of use
ATE486127T1 (en) RESTORATION OF ACTIVITY OF 5-ENOLPYRUVYLSHIKIMAT-3-PHOSPHATE SYNTHASE BY FRAGMENT COMPLEMENTATION
DE602006008460D1 (en) NEW Aβ BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application